Your browser doesn't support javascript.
loading
Pituitary macroadenomas in childhood and adolescence: a clinical analysis of 7 patients.
Aguilar-Riera, Cristina; Clemente, María; González-Llorens, Núria; Mogas, Eduard; Campos-Martorell, Ariadna; Fàbregas, Anna; Biagetti, Betina; Vázquez, Elida; Yeste, Diego.
Afiliación
  • Aguilar-Riera C; Pediatric Endocrinology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain. c_aguilarriera@hotmail.com.
  • Clemente M; Pediatric Endocrinology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • González-Llorens N; CIBER Enfermedades Raras, Instituto Carlos III, Madrid, Spain.
  • Mogas E; Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Campos-Martorell A; Pediatric Endocrinology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Fàbregas A; Pediatric Endocrinology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Biagetti B; Pediatric Endocrinology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Vázquez E; Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Yeste D; Pediatric Endocrinology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Clin Diabetes Endocrinol ; 9(1): 5, 2023 Oct 31.
Article en En | MEDLINE | ID: mdl-37908013
ABSTRACT

BACKGROUND:

Pituitary adenomas (PPAs) are uncommon in childhood and adolescence, accounting for 2-6% of all intracranial neoplasms. Delayed puberty, growth retardation, galactorrhea and weight gain are common features at presentation in pediatric patients. Functional tumors constitute a vast majority (90%) of PPAs, with the most frequent being prolactinomas. CASE PRESENTATION A retrospective review of the clinical features and outcomes of 7 pediatric patients with pituitary macroadenomas was conducted. We included PPAs in patients under 18 years at diagnosis with diameters larger than 10 mm by magnetic resonance (MRI). Six patients were males (85%), with age at diagnosis ranging from 8 to 15 (median 14 ± 2.8SDS). The primary symptoms that led to medical attention were growth retardation, gigantism and secondary amenorrhea. The visual field was reduced in three cases (42%). Suprasellar extension was present in 3 subjects, and one had a giant adenoma. Adenomas were clinically functioning in 6 patients (85%) (three prolactinomas, two somatropinomas, one secreting FSH and one no-producer). The prolactinomas responded to treatment with cabergoline. For the rest, one required transsphenoidal surgery and the other three both surgery and radiotherapy. All patients undergoing radiotherapy had secondary panhypopituitarism. In relation to the genetic studies, two patients presented a pathogenic mutation of the AIP gene and one of the MEN1. DISCUSION AND

CONCLUSION:

Pediatric pituitary macroadenomas are a distinct entity, mostly found in males and with a predominance of functional tumors leading to detrimental effects on growth and puberty in addition to neuro-ophthalmological manifestations. It is important to perform genetic studies in patients with macroadenomas appearing under the age of 18 years as genetic and syndromic associations are more frequent in this age group.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Clin Diabetes Endocrinol Año: 2023 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Clin Diabetes Endocrinol Año: 2023 Tipo del documento: Article País de afiliación: España